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Abstract
Prostate cancer (PC) is one of the most frequent malignancies in Western countries. At
initial diagnosis, bone metastases are present in 15–30% of cases. These metastases cause
some complications including bone fracture,  hypercalcemia,  and bone pain,  which
significantly affect patients’ quality of life. Radionuclide treatment was created as an
alternative to external palliative radiotherapy in the treatment of bone pain arising from
bone metastasis of PC. The basic principle of the radionuclide treatment of pain is that
the uptake of radioactive material is kept in a high amount that is enough to consti‐
tute a proper clinical impact in the tumor, and it is kept at a low dose enough to avoid
the occurrence of significant adverse effects in other organs (commonly in the bone
marrow).  Samarium-153  ethylenediaminetetramethylenephosphonic  acid  (153Sm-
EDTMP) is a radiopharmaceutical compound that has an affinity for skeletal tissue and
concentrates  in  areas  of  increased bone turnover,  localizes  in  the  skeleton,  and is
excreted via glomerular filtration. Medical staff preparing and administering radio‐
pharmaceuticals in nuclear medicine, whether for diagnostic imaging or for therapeu‐
tic application, may receive significant radiation doses to their hands, particularly the
fingers. Sm-153 treatment can be used as an effective and safe treatment alternative in
the management of metastatic bone pain. Radiation protection of the public and the
environment after Sm-153 EDTMP therapy is important.
Keywords: Sm-153 therapy, radiation dose, bone palliation, prostate cancer, radionu‐
clide therapy
1. Introduction
Prostate cancer is one of the most common malignancies worldwide and the third most common
cause of death from cancer in men. In advanced prostate cancer, spread of the disease to the
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skeleton occurs in the majority of patients, with skeletal metastases being predominantly
osteoblastic in nature [1, 2]. Bone metastasis is a common sequela of solid malignant tumors
such as prostate, breast, lung, and renal cancers, which can lead to various complications,
including fractures, hypercalcemia, and bone pain, as well as reduced performance status and
quality of life [3]. A multidisciplinary approach is often required not only to differentiate the
specific cause of the pain but also for appropriate patient management. Several radiopharma‐
ceuticals for treating painful bone metastases have been developed [3]. Radiation is of proven
benefit for pain palliation, and there is growing interest in the therapeutic potential of bone-
seeking radiopharmaceuticals [4]. Radionuclide therapy has been proposed as an alternative
modality for the management of bone pain. These radiopharmaceuticals localize preferential‐
ly in active bone and, mainly, at metastatic lesions, allowing site-directed radiotherapy [1].
The basic principle of the radionuclide treatment of pain is that the uptake of radioactive
material is kept in a high amount that is enough to constitute a proper clinical impact in the
tumor, and it is kept at a low dose enough to avoid the occurrence of significant adverse effects
in other organs (commonly in the bone marrow where more side effects were seen) [5]. One
of the most important advantages of the pain treatment with radionuclide agents is the
repeatability of the procedure [3]. The radioactive isotopes of P-32 and Sr-39 are the initial
radiopharmaceuticals in radionuclide treatment of painful bone metastasis and most recently,
Sm-153[4]. Sm-153 EDTMP is an effective treatment of painful bone metastases from different
neoplasms. However, there are few studies describing clinical experience with this therapeutic
modality. Medical staff preparing and administering radiopharmaceuticals in nuclear
medicine, whether for diagnostic imaging or for therapeutic application, may receive signifi‐
cant radiation doses to their hands, particularly to the fingers. People occupationally exposed
to radiation must have the relevant technical knowledge and competence, that is, must at least
be aware of radiation protection rules and dose-optimized work practices.
The aim of this chapter was to evaluate the efficacy of Sm-153 EDTMP. The objective is to
evaluate extremity doses and dose distributions across the hands of the medical staff working
in Nuclear Medicine departments.
2. Main text
2.1. Prostate cancer
Prostate cancer is the most commonly diagnosed male malignancy. Prostate cancer is the
most prevalent nonskin cancer among men in the United States and is the second leading
cause of cancer deaths in men [6].
Prostate-specific membrane antigen (PSMA) is a cell surface protein with a significantly
increased expression in prostate cancer cells when compared to other PSMA-expressing tissues
such as the small intestine, renal tubular cells, or salivary glands. It therefore provides a
promising target for prostate cancer–specific imaging and therapy. Recently, procedures have
been developed to label PSMA with 68Ga, 99mTc, and radioiodine for positron emission
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tomography (PET) or single photon emission computed tomography (SPECT) imaging and
therapy [7].
Choline-PET/CT is the most promising whole-body imaging modality in detecting distant
metastases of prostate cancer, because of its ability to depict small pathological lymph nodes
and bone metastases with a high sensitivity, specificity, and accuracy. This feature is of primary
importance on management of patients with prostate cancer and for evaluating their progno‐
sis, thanks to the possibility to assess in a single session both anatomic and metabolic infor‐
mation about the disease [8]. There are several papers about the role of Ch-PET in primary
prostate cancer detection and its role in staging prostatic disease before treatment. However,
since the Ch uptake can occur in some benignant conditions, such as prostatitis or prostatic
hyperplasia, the role of this technique in this field is still not well clear.
The 11C-Ch is characterized by a short half-life (approximately 20.4 min), and for this reason,
its use is allowed only in centers provided with a cyclotron. In consideration of the logistical
limitations of the use of 11C-Ch, Ch was subsequently labeled with 18F, which, thanks to the
increased half-life (109.8 min), allows storage and transport. However, 18F-Ch radiotracer is
characterized by an increased urinary excretion compared to 11C-Ch [9].
Bone metastases are the most common and severe complication in patients diagnosed with
primary tumors. Skeletal metastases are clinically significant because of associated symptoms,
complications such as pathological fracture significance for staging, treatment, and prognosis.
It develops in up to 70% of patients diagnosed with prostate cancer and breast cancer. Skeletal-
related events can reduce the health-related quality of life secondary to debilitating pain,
paralysis, loss of mobility, and hospitalization. Systemic palliative-targeted therapy with
suitable radiopharmaceuticals has emerged as a particularly appealing and efficient treatment
modality for patients with multiple skeletal metastases [9].
There are essentially three main types of particulate radiations that are of interest for palliative
treatment of bone metastasis using radiopharmaceuticals: beta (β−) particles, alpha (α)
particles, and Auger electrons. Traditionally, tumor-targeted radiotherapy has used β−-
emitting radionuclides. However, high-energy β− particles, with a range of several millimeters
in tissues, can irradiate cells nearby the targeted tumor. Conversely, α particles (typical
penetration range of <100 μm) and Auger electrons (penetration range of several nanometers
to micrometers) have shorter penetration ranges and higher linear energy transfer (LET) [9].
In recent years, several reports have been published describing the use of multiple radionu‐
clides in the context of palliative treatment of bone metastases.
2.2. Radionuclide therapy
Pain is the most common symptom in the prostate cancer patients. The incidence and severity
of pain in the last period of the life is increasing. Patients and their relatives may adversely be
affected from the quality of life as a major fear source. However, pain related to prostate cancer
can be treated effectively about 85–90% by applying correct approaches. The remaining 5–15%
of patients with pain can be achieved by applying appropriate surgical techniques. The severity
and frequency of pain in cancer patients depends on many factors such as age of the patients,
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the stage of the disease, and the site of bone metastases. For effective pain treatment, accom‐
panying medical and psychosocial problems of the patients should be evaluated, and then,
appropriate treatment should be done [10].
In recent years, there has been a much greater emphasis on “radionuclide therapies” that are
designed to damage only the cancerous cells. At present, effective targeted radiopharmaceut‐
ical therapeutics have been developed. Radionuclide therapy uses ionizing radiation to
minimize tumors and kill cancer cells. The basic principles in the treatment of radioactive
elements in nuclear medicine, to benefit from the devastating effects generated in the cells.
Therefore, many radionuclides have oncological applications of many proven efficacy and
safety. Radionuclide therapy uses radioactive isotopes, administered either orally or intrave‐
nously, to deliver highly targeted therapy for a range of disorders, enabling the delivery of a
high dose to the target, while minimizing normal tissue toxicity [11].
In targeted radionuclide therapy, the biological effect is obtained by energy absorbed from the
radiation emitted by the radionuclide. Whereas the radionuclides used for diagnostic nuclear
medicine procedures emit gamma rays, which can penetrate highly into the body, the radio‐
nuclides used for radionuclide therapy must emit radiation with a comparatively short range.
Radionuclides emitted beta particles, alpha particle, and Auger electrons for radionuclide
therapy use due to short range and high ionization capability. In some cases, mixed emitters
are used to perform both imaging and therapy with the same radionuclide (e.g., Samari‐
um-153) [11].
Various radiopharmaceuticals have been advanced for the treatment of painful bone meta‐
stases (Table 1). The physical characteristics of these radionuclides are different and have
specific benefits. These radionuclides are administered intravenously or orally and localize the
painful bone metastases with a high target-to-nontarget tissue ratio and a very low concen‐
tration in the normal bone, especially bone marrow. The therapeutic suitability of the radio‐
nuclides is important. So the penetration range of the radionuclides is concerned with the
energy of the electrons. The applications of the radiopharmaceuticals are easily performed
without the need for expensive high-technology equipment. Thus, these agents can be
applicable not only in major medical centers but also in minor hospitals, and the workers have
to be educated to comply with Nuclear Regulatory Commission requirements. These agents
target not only osteoblastic lesions but also lesions containing osteolytic and osteoblastic
components. Most of the patients who are treated observed reduce of pain, thus reducing their
need for analgesics and improving the quality of life and mobility [3, 4].
The studies regarding metastatic bone pain have particularly focused on the metastases of
hormone refractory prostate cancer, which was resistant to the treatment of opioid analgesic.
While radiotherapy is more appropriate in the palliative treatment of localized, regional
metastatic lesions, this management is less applicable in the treatment of diffuse metastatic
lesions. The type of metastatic bone pain is different from other somatic pains, such as visceral,
neuropathic, arthritic, and neuropathic pain. While the severity of pain is less intensive
initially, it will progress a chronicle process including acute pain episodes with increasing
severity subsequently. In this process, the pathophysiology of pain cannot be clearly explained,
and various theories have been proposed [12].
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Abundance (%) Soft-tissue range (mm)
(maximum/minimum)
P-32 14.3 1.7 8/3
Sr-89 50.5 1.4 2.4
Re-186 3.7 1.07 137 9 2.4
Re-188 16.9 2.1 155 3
Sm-153 1.9 0.81 103 29 0.6
Table 1. Physical properties of therapy isotopes for bone pain palliation.
A study reported that the maximal pain response to the treatment occurred at 4–6 weeks after
the treatment [13]. In another study, Silberstein [14] declared that the complete or partial
response to 153Sm treatment was obtained in 62–74% of patients, and this response was
commonly seen 5–10 days after the treatment.
The study investigated the efficacy of 153Sm treatment; complete response rate was found
12.4% and the partial response rate was found 73.4%.
Gul et al. determine the reduction in the analgesic consumption and improvement in the
performance and mobility score of the patients (10).
Alleviating of pain can occurred about within 2–7 days depending on the agent after the first
injection. The repeating injections should be performed as soon as possible after the occurrence
of pain recurrence, if bone marrow reserve is adequate. The clinical usage of radionuclides is
not only limited to the opioid resistant pain. As the result of some trials, it was obviously clear
that the expected long-term efficacy and tolerance could be achieved without requirement of
opioid analgesics. The primary goal of the treatment is to provide better quality of life in daily
activities by minimal drug usage [3].
2.2.1. Therapy radionuclides for bone pain palliation
In the past few years, several radiopharmaceuticals have been improved with bone-seeking
properties that provide palliation of pain to multiple bone metastasis. The most of these are
beta electrons, depositing highly their energy over up to millimeters in the surrounding tissues.
A few of the therapeutic radionuclides emit small amounts of gamma-radiation, allowing for
a scintigraphic imaging. The commonly used radiopharmaceutical for pain palliation is
samarium-153 HEDP. Hematopoietic suppression is the major side effect of radionuclide
therapies, with leukopenia and thrombocytopenia more likely to be clinically significant than
anemia. The physical properties of radiopharmaceuticals are discussed in detail in the
following sections.
2.2.2. Phosphorus-32
Phosphorus-32 is pure beta-emitting radionuclide with a physical half-life of 14.3 days. The
average beta particle energy is 695 keV. The mean and maximum particle ranges in tissue of
Samarium-153 Therapy and Radiation Dose for Prostate Cancer
http://dx.doi.org/10.5772/64670
85
phosphorus are 3 and 8 mm, respectively. P-32 is used orthophosphate compound as palliative
treatment purposes. Approximately 85% of the total phosphate pool is located in the skeleton
bound as inorganic phosphate to the hydroxyapatite matrix. From five to ten percentage of
administered activity is excreted via the kidneys within the first 24 h. Total bone doses in the
range 0.4–1.7 cGy/MBq have been reported [4, 15].
2.2.3. Strontium-89
Strontium-89 is a pure beta-emitter with a beta particle energy of 1.46 MeV and a physical half-
life of 50.5 days [15]. It localizes in bone primarily in areas of osteoblastic activity. It is an mean
particle range in tissue of 2.4 mm. The fix dose is 148 MBq (4 mCi). The radiation dose of
metastatic foci is about 1000–5000 cGy. Bone marrow radiation dose is approximately ten
percent of metastatic foci. 89Sr can be effective at relieve pain from bone metastases, particu‐
larly for metastatic prostate or breast cancer [4].
2.2.4. Rhenium-186
Rhenium-186 is a beta- and gamma-emitting radionuclide. The maximum beta particle energy
is 1.07 MeV. Re-186 has a 137 keV, 9% abundance gamma-photon with a physical half-life of
89.3 h. It is forms a stable diphosphonate chelate with hydroxyethylidene diphosphonate
(HEDP). Rhenium-186 HEDP has rapid urinary excretion. It is excreted about 70% of dose
within 6 h in the urine [4].
2.2.5. Sn-117m
Sn-117m is gamma-emitting radionuclide with 159 keV. Physical half-life of Sn-117m is
13.6 days. It is decays by short-range conversion electrons. Bone marrow toxicity of this
radionuclide is low because of its short range. Therefore, Sn-117m can be used to treat bone
tumors and rheumatoid arthritis [16].
2.2.6. Samarium-153
Samarium-153 is a reactor which produced high radionuclidic purity by neutron bombard‐
ment of enriched 152Sm oxide [3]. Samarium-153 is a beta-emitter with a short half-life (46.7 h),
which also emits gamma-photons suitable for imaging at 103 keV. Samarium-153 principal
radiation emission data are shown in Table 2. The isotope is chelated to ethylene diamine
tetramethylene phosphonate (EDTMP), which targets the bone matrix as a polyphosphonate
(Figures 1 and 2). The therapeutic doses administered to patients about 50% settle in the bone
excretion are through the kidneys. The proportion of skeletal uptake is the highest for the bone-
seeking radiopharmaceuticals. The effective range of 153Sm is 2–3 mm in bone [1]. 153Sm-
EDTMP is indicated for the relief of pain in patients with osteoblastic metastatic bone lesions
at a standard dose of 37 MBq/kg to a maximum of 5550 MBq [1, 2]. Clinical benefit is reported
by 60–80% of patients within 2 weeks of administration, frequently within 48 h, with a response
duration of 4–40 weeks [4].
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*Maximum energies are listed for beta emissions, and the average beta particle energy is 233 keV
Table 2. Samarium-153 principal radiation emission data.
Figure 1. A bone scintigraphy that was obtained before the 153Sm-EDTMP treatment.
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Figure 2. A bone scintigraphy that was obtained after the 153Sm-EDTMP treatment.
This treatment can be repeated several times to the patients. Repeat dosing with 153Sm is both
safe and effective. The studied reports showed that the patients with symptomatic bone
metastases receiving multiple doses of 153Sm have no significant differences in pain reduction
or in myelosuppression after a second or third treatment [17].
Pregnancy, lactation, acute spinal cord compression, single metastatic lesion, renal failure, the
long bone that holds more than 50% of the affected bone metastases, risk of fracture and in the
presence of disseminated intravascular coagulation are the contraindications of pain palliation
with 153Sm therapy.
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2.2.7. Radiation dose
The diagnostic and therapeutic procedures have been continuously increasing in most of the
nuclear medicine facilities. The risk of radiation exposure of staff is of importance due to
increasing procedures. The radiation sources of nuclear medicine Departments are preparing
and administering of the radiopharmaceuticals. The workers may receive significant radiation
dose to their whole body, especially to the hands.
Therapeutic nuclear medicine requires special consideration due to the high doses of radiation.
Therapeutic radionuclides have usually beta electrons. Owing to 153Sm-EDTMP’s intermedi‐
ate beta-energy and low tissue penetration, the bone marrow, for the most part, is spared
throughout the skeleton. For protection, two radiation safety consideration needs to be paid
attention. One of them, external radiation dose of 153Sm, the interaction of high-energy beta
particles with high atomic number materials (e.g., lead) will lead to the production of high-
energy X-rays (Bremsstrahlung). Parlak et al. reported that external radiation dose of 153Sm
is high for the first 8 h (Figure 3). They suggest that hospitalizing the patients treated with
Sm-153 therapy in an isolated room for 8 h would be helpful for radiation protection of the
public. On the other hand, radiation safety consideration is the contamination by excretion of
the 153Sm. The variability of isolation times indicates a strong dependency of effective half-
life on biological excretion and shows no relationship with administered activity. Certainly,
this variability reveals the need to determine these parameters for each patient [1].
Figure 3. Excretion of 153Sm-EDTMP through the urinary tract in the first 24 h.
Developments in nuclear medicine show that applications involving beta-emitters will
probably increase further. Data on the beta-radiation dose equivalents for the staff performing
such treatments are limited. For this reason, additional measures should be provided for the
training and continuing education of the staff in order to avoid any further increase in
extremity doses.
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